Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma
Status:
Recruiting
Trial end date:
2022-12-04
Target enrollment:
Participant gender:
Summary
This Single-arm, multicentre, phase 2 trial aims determine the activity and safety of
pembrolizumab and denosumab in advanced clear cell renal cell carcinoma (ccRCC).
Phase:
Phase 2
Details
Lead Sponsor:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group